| Wright & Filippis Llc | |
| 363 Fremont St, Ste 300, Battle Creek, Michigan 49017 | |
| (269) 979-5760 |
| Name | Wright & Filippis Llc |
|---|---|
| Organization Name | Wright & Filippis Llc |
| Location | 363 Fremont St, Ste 300, Battle Creek, Michigan 49017 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (269) 979-5760 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.
Researchers in the UK, including the University of Oxford and Glasgow, as well as the University of Heidelberg, published their analysis of protein-RNA interactions in SARS-CoV-2 and the subsequent significance in the journal Molecular Cell. This research could help to uncover novel antiviral strategies for COVID-19 due to a broader understanding of how the virus works.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
The first of a two-day, closed-door, HHS meeting with representatives from 44 states suggested that in many cases states will delay passing laws to create health insurance exchanges until 2012, according to one attendee. ... States have flexibility under the law to structure exchanges in different ways. HHS has urged that, if possible, they begin passing legislation in 2011 to get that process underway (Reichard, 12/16).
› Verified 7 days ago
| NPI Number | 1174560320 |
| Organization Name | WRIGHT & FILIPPIS, LLC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 363 Fremont St Ste 300, Battle Creek, MI 49017 |
| Phone Number | 269-979-5760 |
News Archive
Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.
Researchers in the UK, including the University of Oxford and Glasgow, as well as the University of Heidelberg, published their analysis of protein-RNA interactions in SARS-CoV-2 and the subsequent significance in the journal Molecular Cell. This research could help to uncover novel antiviral strategies for COVID-19 due to a broader understanding of how the virus works.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
The first of a two-day, closed-door, HHS meeting with representatives from 44 states suggested that in many cases states will delay passing laws to create health insurance exchanges until 2012, according to one attendee. ... States have flexibility under the law to structure exchanges in different ways. HHS has urged that, if possible, they begin passing legislation in 2011 to get that process underway (Reichard, 12/16).
› Verified 7 days ago
| NPI Number | 1679628739 |
| Organization Name | WRIGHT & FILIPPIS, LLC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 363 Fremont St Ste 300, Battle Creek, MI 49017 |
| Phone Number | 269-979-5760 |
News Archive
Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.
Researchers in the UK, including the University of Oxford and Glasgow, as well as the University of Heidelberg, published their analysis of protein-RNA interactions in SARS-CoV-2 and the subsequent significance in the journal Molecular Cell. This research could help to uncover novel antiviral strategies for COVID-19 due to a broader understanding of how the virus works.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
The first of a two-day, closed-door, HHS meeting with representatives from 44 states suggested that in many cases states will delay passing laws to create health insurance exchanges until 2012, according to one attendee. ... States have flexibility under the law to structure exchanges in different ways. HHS has urged that, if possible, they begin passing legislation in 2011 to get that process underway (Reichard, 12/16).
› Verified 7 days ago
News Archive
Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.
Researchers in the UK, including the University of Oxford and Glasgow, as well as the University of Heidelberg, published their analysis of protein-RNA interactions in SARS-CoV-2 and the subsequent significance in the journal Molecular Cell. This research could help to uncover novel antiviral strategies for COVID-19 due to a broader understanding of how the virus works.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.
The first of a two-day, closed-door, HHS meeting with representatives from 44 states suggested that in many cases states will delay passing laws to create health insurance exchanges until 2012, according to one attendee. ... States have flexibility under the law to structure exchanges in different ways. HHS has urged that, if possible, they begin passing legislation in 2011 to get that process underway (Reichard, 12/16).
› Verified 7 days ago
Rite Aid Pharmacy 04369 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 30 E Columbia Ave, Battle Creek, Michigan 49015 Phone: (269) 965-3237 | |
Cvs Pharmacy #16156 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5700 Beckley Road, Battle Creek, Michigan 49015 Phone: (269) 979-0778 | |
Cvs Pharmacy #10547 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10 Columbia Ave E, Battle Creek, Michigan 49015 Phone: (269) 962-1965 | |
Rite Aid Pharmacy 02425 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 600 North Ave, Battle Creek, Michigan 49017 Phone: (269) 963-1524 | |
Rite Aid #4963 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 890 Michigan Ave E, Battle Creek, Michigan 49014 Phone: (269) 660-9509 |